Stay updated on SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial

Sign up to get notified when there's something new on the SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    - The page revision was updated from v3.6.2 to v3.6.3. This update reflects a version change and does not modify the study content or how users interact with the page.
    Difference
    0.0%
    Check dated 2026-07-06T15:55:31.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The page revision tag was updated to v3.6.2, replacing the previous v3.6.0. This indicates a minor update to the site's template or content management without altering the study content.
    Difference
    0.0%
    Check dated 2026-06-29T08:51:34.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    The page adds a recruitment-closed notice and new user-help sections (How to Read a Study Record, Common Questions, How to Join a Study); the Intervention/Treatment header is updated and the revision version is changed to v3.6.0.
    Difference
    0.2%
    Check dated 2026-06-15T05:52:41.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    Footer text now shows Revision: v3.5.5, replacing Revision: v3.5.4. This indicates a version tag update for the page rather than a change to study content.
    Difference
    0.0%
    Check dated 2026-06-08T03:51:52.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.5.4, replacing v3.5.3, representing a minor version update.
    Difference
    0.0%
    Check dated 2026-05-17T09:29:27.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    ClinicalTrials.gov updated the study record revision/date and refined the treatment regimen details (e.g., calaspargase pegol administration description) and monitoring language for trial procedures. It also updated key eligibility/evaluability and primary/expansion outcome descriptions, including the DLT evaluability thresholds for dose-finding and how MRD-negative remission is described for patients under 6 months.
    Difference
    0.9%
    Check dated 2026-04-25T05:27:47.000Z thumbnail image

Stay in the know with updates to SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial page.